BRPI0819936A2 - Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação. - Google Patents
Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.Info
- Publication number
- BRPI0819936A2 BRPI0819936A2 BRPI0819936-1A BRPI0819936A BRPI0819936A2 BR PI0819936 A2 BRPI0819936 A2 BR PI0819936A2 BR PI0819936 A BRPI0819936 A BR PI0819936A BR PI0819936 A2 BRPI0819936 A2 BR PI0819936A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- dendritic cells
- dendritic
- pharmaceutical
- producing
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07450233A EP2072617A1 (en) | 2007-12-12 | 2007-12-12 | Method for producing dendritic cells |
PCT/EP2008/010606 WO2009074341A1 (en) | 2007-12-12 | 2008-12-12 | Method for producing dendritic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0819936A2 true BRPI0819936A2 (pt) | 2015-05-26 |
Family
ID=39325869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0819936-1A BRPI0819936A2 (pt) | 2007-12-12 | 2008-12-12 | Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9303246B2 (pt) |
EP (2) | EP2072617A1 (pt) |
JP (1) | JP5730577B2 (pt) |
KR (1) | KR101590199B1 (pt) |
CN (1) | CN101896601B (pt) |
AU (1) | AU2008334914B9 (pt) |
BR (1) | BRPI0819936A2 (pt) |
CA (1) | CA2709209C (pt) |
EA (1) | EA023106B1 (pt) |
MX (1) | MX2010006434A (pt) |
NZ (1) | NZ585898A (pt) |
WO (1) | WO2009074341A1 (pt) |
ZA (1) | ZA201003193B (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
CN102006891B (zh) | 2008-02-13 | 2017-04-26 | 哈佛学院董事会 | 连续的细胞程序化装置 |
WO2011063336A2 (en) * | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
WO2009146456A1 (en) | 2008-05-30 | 2009-12-03 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
US8728456B2 (en) | 2009-07-31 | 2014-05-20 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
US9610328B2 (en) | 2010-03-05 | 2017-04-04 | President And Fellows Of Harvard College | Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1 |
JP2013522309A (ja) * | 2010-03-15 | 2013-06-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 活性化した成熟樹状細胞を調製し保存するシステムおよび方法 |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES |
EP2624873B1 (en) | 2010-10-06 | 2019-12-04 | President and Fellows of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
WO2012064697A2 (en) | 2010-11-08 | 2012-05-18 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
US10647959B2 (en) | 2011-04-27 | 2020-05-12 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
EP3417876B1 (en) | 2011-04-28 | 2021-03-31 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
US9486512B2 (en) | 2011-06-03 | 2016-11-08 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
LT2838515T (lt) | 2012-04-16 | 2020-03-10 | President And Fellows Of Harvard College | Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui |
EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
JP6434139B2 (ja) * | 2014-06-23 | 2018-12-05 | ジェイダブリュ クレアジェン インコーポレイテッド | 特定遺伝子発現が増加した樹状細胞の製造方法およびこれを利用して製造された樹状細胞を含む自己免疫疾患治療または予防用組成物 |
KR101477106B1 (ko) * | 2014-07-14 | 2014-12-29 | 동아대학교 산학협력단 | 나노-마이크로 하이브리드 섬유 기반의 미성숙 수지상세포 배양방법 및 분석방법 |
EP3929302A1 (en) | 2014-07-14 | 2021-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
CN105821030A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 表达α1,3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
CN104630145A (zh) * | 2015-01-12 | 2015-05-20 | 杨世成 | 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物 |
CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
WO2016164705A1 (en) | 2015-04-10 | 2016-10-13 | Omar Abdel-Rahman Ali | Immune cell trapping devices and methods for making and using the same |
CN107849537A (zh) | 2015-06-30 | 2018-03-27 | 西北生物治疗药物公司 | 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞 |
DK3350318T3 (da) * | 2015-09-15 | 2022-07-11 | Northwest Biotherapeutics Inc | Fremgangsmåder relateret til aktiverede dendritiske cellesammensætninger til individer med fremskredne cancersygdomme |
CN105219721A (zh) * | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活胰腺癌特异性免疫反应的试剂盒 |
CN105219714A (zh) * | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活肺癌特异性免疫反应的试剂盒 |
CN105219715A (zh) * | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活食管癌特异性免疫反应的试剂盒 |
CN105219720A (zh) * | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活肝癌特异性免疫反应的试剂盒 |
AU2016343845B2 (en) * | 2015-10-30 | 2023-04-13 | Baylor College Of Medicine | Compositions and methods for the treatment of HER2-expressing solid tumors |
CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
CN109789092A (zh) | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
KR102356510B1 (ko) * | 2017-09-05 | 2022-02-08 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 효능 분석 |
CN109468275B (zh) * | 2018-07-25 | 2021-01-08 | 中国人民解放军军事科学院军事医学研究院 | 一种树突状细胞诱导剂及其制备方法与应用 |
CN114032212B (zh) * | 2022-01-10 | 2022-04-19 | 北京荟科柘生物科技有限公司 | 一种提高抗原呈递t细胞并提高t细胞杀伤效率的dc细胞制备方法及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
US7847156B2 (en) * | 2003-10-20 | 2010-12-07 | Cropdesign N.V. | Plants having improved growth characteristics and methods for making the same |
PT1567155E (pt) * | 2002-12-06 | 2011-01-28 | Northwest Biotherapeutics Inc | Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
AU2005294150B2 (en) * | 2004-10-07 | 2011-06-16 | Coimmune, Inc. | Mature dendritic cell compositions and methods for culturing same |
US8440610B2 (en) * | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
-
2007
- 2007-12-12 EP EP07450233A patent/EP2072617A1/en not_active Withdrawn
-
2008
- 2008-12-12 US US12/747,759 patent/US9303246B2/en active Active
- 2008-12-12 CA CA2709209A patent/CA2709209C/en active Active
- 2008-12-12 WO PCT/EP2008/010606 patent/WO2009074341A1/en active Application Filing
- 2008-12-12 EP EP08859543.4A patent/EP2222836B1/en active Active
- 2008-12-12 KR KR1020107011455A patent/KR101590199B1/ko active IP Right Grant
- 2008-12-12 JP JP2010537327A patent/JP5730577B2/ja active Active
- 2008-12-12 MX MX2010006434A patent/MX2010006434A/es active IP Right Grant
- 2008-12-12 EA EA201000972A patent/EA023106B1/ru not_active IP Right Cessation
- 2008-12-12 CN CN200880120431.4A patent/CN101896601B/zh active Active
- 2008-12-12 AU AU2008334914A patent/AU2008334914B9/en active Active
- 2008-12-12 NZ NZ585898A patent/NZ585898A/en not_active IP Right Cessation
- 2008-12-12 BR BRPI0819936-1A patent/BRPI0819936A2/pt not_active Application Discontinuation
-
2010
- 2010-05-06 ZA ZA2010/03193A patent/ZA201003193B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101896601A (zh) | 2010-11-24 |
CA2709209A1 (en) | 2009-06-18 |
NZ585898A (en) | 2012-01-12 |
EP2222836A1 (en) | 2010-09-01 |
JP2011506372A (ja) | 2011-03-03 |
EP2072617A1 (en) | 2009-06-24 |
ZA201003193B (en) | 2011-10-26 |
CN101896601B (zh) | 2014-09-03 |
JP5730577B2 (ja) | 2015-06-10 |
EP2222836B1 (en) | 2017-02-22 |
EA201000972A1 (ru) | 2010-12-30 |
KR101590199B1 (ko) | 2016-01-29 |
US20100285072A1 (en) | 2010-11-11 |
MX2010006434A (es) | 2011-05-02 |
KR20100101094A (ko) | 2010-09-16 |
AU2008334914B2 (en) | 2013-08-01 |
EA023106B1 (ru) | 2016-04-29 |
AU2008334914A1 (en) | 2009-06-18 |
AU2008334914B9 (en) | 2013-09-26 |
CA2709209C (en) | 2019-05-21 |
US9303246B2 (en) | 2016-04-05 |
WO2009074341A1 (en) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0819936A2 (pt) | Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação. | |
BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
BRPI0916689A2 (pt) | composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. | |
BRPI0922174A2 (pt) | preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica | |
BRPI0816330A2 (pt) | Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina | |
BRPI0817154A2 (pt) | "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol" | |
BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
BRPI1014800A8 (pt) | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" | |
BRPI0918359A2 (pt) | composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto | |
BRPI0818680A2 (pt) | composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica | |
BRPI1009981A2 (pt) | sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula | |
IL194438A (en) | Diarrhylthiohydantoin Compounds, Pharmaceuticals Containing Them, Syntheses Methods and In Vitro Methods for Contacting them with Mammalian Cells | |
BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
IL205360A0 (en) | Methods, kits, and compositions for administering pharmaceutical compounds | |
BRPI0918487A2 (pt) | processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero | |
BR112012001329A2 (pt) | métodos para obter células com uma potência desejada, para tratar inflamação em um sujeito, para construir um banco de células, para descoberta de droga e para aumentar a potência de uma célula, e, composição. | |
BR112012009609A2 (pt) | método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições | |
BRPI0808034A2 (pt) | Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel. | |
BRPI1010617A2 (pt) | uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição. | |
BRPI0914918A2 (pt) | forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida. | |
BRPI0807220B1 (pt) | composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
BRPI0719272A2 (pt) | Composição de enzima, e, método para preparar uma composição de enzima. | |
BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |